Skip to main content
NIH funding notice PAR-23-157

Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)

Closed on May 23, 2025.

Posted
April 10, 2023
Close date
May 23, 2025
Activity codes
R61, R33
Institutes taking part
NIDA

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

  1. Reissues: PAR-19-282 Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
  2. 2 steps back: PAR-23-158 Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)

Replaced by PAR-27-053.

Who won it before

8 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,242,971 in first-year total cost, median $408,769.

Most frequent study sections

  1. Addiction Risks and Mechanisms Study Section[ARM]4
  2. Adult Psychopathology and Disorders of Aging Study Section[APDA]1
  3. Biobehavioral Regulation, Learning and Ethology Study Section[BRLE]1
  4. Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section[NPAS]1
  5. Special Emphasis Panel[ZRG1 BDCN-G (90)]1

Most frequent institutions

  1. STATE UNIVERSITY NEW YORK STONY BROOK2
  2. ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI1
  3. PENNSYLVANIA STATE UNIV HERSHEY MED CTR1
  4. RUTGERS BIOMEDICAL AND HEALTH SCIENCES1
  5. UNIVERSITY OF PENNSYLVANIA1
Competing awards under PAR-23-157 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Combined guanfacine and mindfulness meditation as an adjunct to buprenorphine maintenance in OUD1R61DA059906-01A1 · under PAR-23-158FOX, HELEN CECILIARAY, SUCHISMITARUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ$421,621ARM
2024Bayesian neurobehavioral phenotyping: from mechanism identification to personalized neuromodulation treatments1R61DA058276-01A1 · under PAR-19-282KYPRIOTAKIS, GEORGEVERSACE, FRANCESCOUNIVERSITY OF TX MD ANDERSON CAN CTR, TX$408,302ARM
2023Cue Reactivity Modulation in MSM with Methamphetamine Use Disorder1R61DA056779-01A1 · under PAR-19-282PARVAZ, MUHAMMAD ADEELICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY$412,562BRLE
2022Assessing central muscarinic acetylcholine type-1 receptors in cocaine use disorder with 11C-LSN3172176.1R61DA053592-01A1 · under PAR-19-282WORHUNSKY, PATRICK DYALE UNIVERSITY, CT$431,237NPAS
2022Postpartum Intervention for Mothers with Opioid Use Disorders - Brain-Behavior Mechanisms1R61DA053688-01A1 · under PAR-19-282MUZIK, MARIASWAIN, JAMES EDWARDSTATE UNIVERSITY NEW YORK STONY BROOK, NY$409,235ARM
2022A human translation of research on the neurobehavioral reward and reinforcement of flavored electronic nicotine delivery systems (ENDS)1R61DA056764-01 · under PAR-19-282HOBKIRK, ANDREAPENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA$396,126ARM
2022Deep rTMS modulating insula synaptic density and smoking behavior in schizophrenia1R61DA056423-01 · under PAR-19-282ABI-DARGHAM, ANISSAMOELLER, SCOTT JSTATE UNIVERSITY NEW YORK STONY BROOK, NY$358,623ZRG1
2021Brain Mechanisms of Cognitive Response to Pharmacotherapy in Opioid Use Disorder1R61DA051625-01A1 · under PAR-19-282LOUGHEAD, JAMES WUNIVERSITY OF PENNSYLVANIA, PA$405,265APDA

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-23-157: Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) | ScienceDex | ConductScience